Please login to the form below

Not currently logged in
Email:
Password:

Onpattro

This page shows the latest Onpattro news and features for those working in and with pharma, biotech and healthcare.

Alnylam scores EU approval for RNAi drug Givlaari

Alnylam scores EU approval for RNAi drug Givlaari

Alnylam’s first RNAi drug – Onpattro (patisiran) for rare disease hereditary ATTR amyloidosis – has a similar pricing strategy. ... Onpattro, on the other hand, launched with a $450, 000 per year price tag, and subsequently dropped to $345, 000

Latest news

More from news
Approximately 7 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    Onpattro was approved to treat adults with the. destruction of nerves that results from a rare disease, hereditary transthyretin- mediated (hATTR) amyloidosis, and was launched with a $450, 000 per year ... The company has tried to be creative with its

  • Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

    Alnylam's Theresa Heggie. Alnylam and its extraordinary ‘gene silencing’ technology is making its debut in Europe with the launch of Onpattro. ... PME talks to its European leader Theresa Heggie. Even as it launches its first ever product Onpattro,

More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics